克拉屈滨或氯法拉滨联合低剂量阿糖胞苷交替地西他滨治疗老年初诊AML的长期结果
该研究回顾性分析了2008至2018年间两项临床试验中248例初诊非核心结合因子急性髓系白血病(AML)老年患者,接受氯法拉滨或克拉屈滨联合低剂量阿糖胞苷交替地西他滨的低强度化疗。中位随访60个月,总缓解率66%(完全缓解59%),中位总生存12.5个月,2年总生存29%,4周和8周死亡率分别为2%和11%。该方案对老年初诊AML有效且安全。
要点
- 老年初诊AML患者采用双核苷类似物联合低剂量阿糖胞苷交替去甲基化药物方案,总缓解率66%。
- 中位总生存12.5个月,2年总生存29%,4周死亡率仅2%。
- 正常核型患者完全缓解/完全缓解伴计数不完全恢复率79%,中位总生存19.9个月。
核心结论
- 氯法拉滨或克拉屈滨联合低剂量阿糖胞苷交替地西他滨的方案对老年初诊AML有效且安全。
研究设计与样本
- 回顾性分析两项临床试验中共248例初诊非核心结合因子AML老年患者,中位年龄69岁(范围49-85岁),其中102例(41%)≥70岁,108例(44%)核型不良。
主要发现
- 总体缓解164例(66%),其中完全缓解147例(59%),完全缓解伴计数不完全恢复17例(7%)。
- 中位随访60个月,中位无复发生存10.8个月,中位总生存12.5个月,2年总生存29%。
- 正常核型患者完全缓解/完全缓解伴计数不完全恢复率79%,中位总生存19.9个月。
- NPM1、FLT3、IDH2和RUNX1突变患者观察到高缓解率和总生存。
- 4周死亡率为2%,8周死亡率为11%。
临床怎么用
- 该低强度方案可作为老年初诊AML患者的治疗选择,尤其适合不适合强化化疗者。
- 治疗相关早期死亡率低,4周死亡率仅2%,支持其安全性。
局限性
- 研究为回顾性分析,样本来自两项临床试验,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The treatment of older patients with newly diagnosed acute myeloid leukemia (AML) using intensive chemotherapy is associated with treatment intolerance and poor survival. We evaluated two new lower-intensity regimens with clofarabine (n = 119) or cladribine (n = 129) combined with low-dose cytarabine (LDAC) alternating with decitabine. We reviewed response rates by subgroup and long term outcomes of 248 patients with newly diagnosed non core-binding-factor AML treated on two clinical trials investigating double nucleoside-analogue therapy (DNT) alternating with HMA from October, 2008 to April, 2018. Of 248 patients with a median age of 69 years (range, 49-85 years), 102 patients (41%) were ≥ 70 years, and 108 (44%) had adverse karyotype. Overall, 164 patients (66%) responded: 147 (59%) complete remission (CR) and 17 (7%) CR with incomplete count recovery (CRi). With a median follow up of 60 months, median relapse-free and overall survival (OS) were 10.8 and 12.5 months, respectively. The 2-year OS was 29%. Among patients with normal karyotype, the CR/CRi rate was 79% and the median OS 19.9 months. High response rates and OS were observed in patients with mutations in NPM1, FLT3, IDH2, and RUNX1. The 4- and 8-week mortality rates were 2% and 11%, respectively. The backbone of clofarabine or cladribine and LDAC alternating with decitabine was effective and safe for the treatment of older patients with newly diagnosed AML. Incorporating targeted therapies could extend the efficacy of this approach and provide more curative therapeutic options in this AML population.
引用
- Kadia TM, Ravandi F, Borthakur G, et al. Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Am J Hematol. 2021. PMID: 33901324. doi:10.1002/ajh.26206
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。